You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

C'Dot drug conjugate

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CBFA2T3-GLIS2-positive Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML Trial (ELU001)

Not yet recruiting
  • CBFA2T3-GLIS2-positive Acute Myeloid Leukemia
  • +3 more
  • (no location specified)
Nov 14, 2022

Solid Tumor Trial in Worldwide (BYON3521)

Recruiting
  • Solid Tumor
  • Brussels, Belgium
  • +3 more
Aug 2, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in United States (ELU001)

Recruiting
  • Ovarian Cancer
  • +68 more
  • Phoenix, Arizona
  • +8 more
Aug 18, 2022

HEPATITIS C, Virus, Human Immunodeficiency Trial in Aurora (Directly Observed Therapy, Wirelessly Observed Therapy)

Completed
  • HEPATITIS C
  • Virus, Human Immunodeficiency
  • Directly Observed Therapy
  • Wirelessly Observed Therapy
  • Aurora, Colorado
    University of Colorado Anschutz Medical Campus
Mar 4, 2022

Solid Tumor Trial in United States (TR1801-ADC)

Active, not recruiting
  • Unspecified Adult Solid Tumor, Protocol Specific
  • TR1801-ADC
  • Los Angeles, California
  • +4 more
Oct 30, 2022

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

Completed
Has Results
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Sep 22, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,

Recruiting
  • High Grade Serous Ovarian Cancer
  • +2 more
  • Upifitimab rilsodotin
  • Placebo
  • Phoenix, Arizona
  • +40 more
Jan 25, 2023

Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myeloid Neoplasm
  • Biospecimen Collection
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 5, 2023

Typhoid Trial in Dhaka (Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT))

Not yet recruiting
  • Typhoid
  • Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)
  • Dhaka, Bangladesh
    International Centre for Diarrhoeal Disease Research, Bangladesh
Jul 25, 2022

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Epidemic Meningitis Trial (MCV4)

Not yet recruiting
  • Epidemic Meningitis
  • MCV4
  • (no location specified)
Jul 5, 2023

NSCLC Trial in Worldwide (MORAb-202)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Lone Tree, Colorado
  • +21 more
Jan 17, 2023

DLBCL, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Tampa, Florida
  • +1 more
Jan 12, 2022

Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • STI-6129
  • Beijing, Beijing, China
  • +3 more
Jan 9, 2023

Gastrointestinal Tumors; Esophageal, Stomach, Pancreas, Colon Tumors; Malignant Tumors of Digestive Organ; Advanced

Terminated
Has Results
  • Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
  • Aurora, Colorado
  • +3 more
Feb 24, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Neuroendocrine Carcinomas
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Sep 22, 2023

Ovarian Cancer, Lung Adenocarcinoma Trial in United States (AZD5335, AZD5305)

Not yet recruiting
  • Ovarian Cancer
  • Lung Adenocarcinoma
  • Duarte, California
  • +6 more
Mar 21, 2023

Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7 Trial in United States

Recruiting
  • Breast Adenocarcinoma
  • +7 more
  • Multi-epitope HER2 Peptide Vaccine TPIV100
  • +5 more
  • Scottsdale, Arizona
  • +26 more
Aug 17, 2022

NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

Not yet recruiting
  • NSCLC
  • +5 more
  • (no location specified)
Dec 7, 2022

Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma Trial (AMT-151)

Not yet recruiting
  • Advanced Solid Tumor
  • +18 more
  • (no location specified)
Aug 10, 2022

Pneumococcal Infection Trial (V116, Placebo for PCV15 + PPSV23, PCV15)

Not yet recruiting
  • Pneumococcal Infection
  • V116
  • +3 more
  • (no location specified)
Jan 13, 2023

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large

Recruiting
  • Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 10, 2022